Ligand Pharmaceuticals Inc (NASDAQ:LGND)
| 71.15 Delayed Data As of Mar 21 |  -0.50 / -0.70%Today’s Change | 45.25 Today|||52-Week Range 83.95 | +6.51% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $1.3B |
Company Description
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.
Contact Information
Ligand Pharmaceuticals, Inc. 3911 Sorrento Valley Boulevard San Diego California 92121 |
Employees
Shareholders
| Mutual fund holders | 60.52% |
| Individual stakeholders | 31.87% |
| Other institutional | 28.97% |
Top Executives
| Todd C. Davis | Chief Executive Officer & Director |
| Matthew Edward Korenberg | President & Chief Operating Officer |
| Octavio Espinoza | Chief Financial Officer |
| Simon Latimer | Investors Relations Manager |
| Audrey Warfield-Graham | Chief People Officer |
